These shares demonstrate why buy and hold investing can be a great strategy for investors. The post 3 ASX 200 shares that ...

The global respiratory diagnostics market, valued at US$ 5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$ ...

We profile four US stocks that burst past their year-high to determine if they should be in your growth stocks portfolio.

Discover 9 top dividend stocks with 10%+ 5-year return potential based on my valuations and in-depth analysis. Click here.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Analysts are bullish on these names. Let's find out why they rate them as buys. The post Where to invest $10,000 into ASX 200 ...

UBS analyst Laura Sutcliffe maintained a Hold rating on Ansell (ANSLF – Research Report) today and set a price target of A$36.00. The company’s ...

A look at the shareholders of ResMed Inc. (NYSE:RMD) can tell us which group is most powerful. With 69% stake, institutions possess the maximum shares in the company. In other words, the group stands ...

Not getting enough ZZZs or going to bed late into the night can have an adverse impact on your health and well being. Here’s ...

William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...